Low Risk of Development of a Regional Recurrence After an Unsuccessful Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

Ingrid G. M. Poodt*, Coco J. E. F. Walstra, Guusje Vugts, Adriana J. G. Maaskant-Braat, Adri C. Voogd, Robert-Jan Schipper, Grard A. P. Nieuwenhuijzen, R. M. H. Roumen, E. J. T. Luiten, E. J. T. Rutgers, M. T. F. D. Vrancken-Peeters, M. Bessems, M. Klaase, S. Muller, A. B. Francken, T. Van Dalen, L. Jansen, S. A. Koopal, Y. L. J. Vissers, M. L. SmidtJ. W. S. Merkus, C. M. E. Contant, P. H. Veldman, E. M. H. Linthorst-Niers, J. R. van der Sijp, O. R. Guicherit, L. B. Koppert, A. M. Bosch, L. J. A. Strobbe, M. S. Schlooz-Vries, I. E. Arntz, J. A. van Essen, J. W. D. de Waard, B. C. Vrouenraets, B. van Ooijen, Sentinel Node Recurrent Breast

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)

Abstract

BackgroundUnlike sentinel lymph node biopsy (SLNB) in the primary setting, the repeat SLNB (rSLNB) in patients with ipsilateral breast tumor recurrence (IBTR) is challenging, because it is difficult to visualize and/or harvest a sentinel lymph node in every patient. Regional treatments options and safety in terms of regional disease control after such an unsuccessful rSLNB remain unclear. This study assesses factors associated with the performance of axillary lymph node dissection (ALND) after unsuccessful rSLNB and evaluates the occurrence of regional recurrences.MethodsData were obtained from the Sentinel Node and Recurrent Breast Cancer (SNARB) study. In 239 patients, the rSLNB was unsuccessful, of whom 60 patients underwent ipsilateral ALND.ResultsA shorter time interval between primary treatment and IBTR, and a primary negative SLNB were significantly associated with a higher probability to be treated with ALND after unsuccessful rSLNB (P0.05).ConclusionsThe present study demonstrates that the risk of regional recurrence in patients with an IBTR and an unsuccessful rSLNB is negligible, irrespective of the use of ALND. This suggests that there is no need for additional treatment of the axilla after an unsuccessful rSLNB.

Original languageEnglish
Pages (from-to)2417-2427
Number of pages11
JournalAnnals of Surgical Oncology
Volume26
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • EUROPEAN INSTITUTE
  • CANCER
  • TRIAL
  • RADIOTHERAPY
  • METASTASIS
  • FIBROSIS
  • SURGERY
  • AXILLA
  • WOMEN

Cite this